ImExHS Limited (IME) AI Stock Analysis

• Market Cap: AU$15.10M
• Dividend Yield: N/A
• Average Volume (3M): 41.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: 6.77%
• EPS Growth: -8.45%
• Country: AU
• Employees: 400
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.06
• Shares Outstanding: 53,916,676
• 10 Day Avg. Volume: 23,052
• 30 Day Avg. Volume: 41,775
• PEG Ratio: 0.15
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 0.63
• P/FCF Ratio: -9.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: AU$0.50 ▲(47.06% Upside)

ImExHS Limited's overall stock score is driven by strong technical indicators showing bullish momentum, despite challenges in profitability and valuation. The company's financial performance is mixed, with strong revenue growth but negative profitability metrics. The lack of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Equity Position

A stable equity position enhances financial resilience, providing a solid foundation for future investments and growth initiatives.

Low Financial Leverage

Low financial leverage reduces risk and interest burden, allowing more flexibility in financial planning and operational execution.

Negative Factors

Profitability Challenges

Continued unprofitability can hinder reinvestment and growth opportunities, requiring strategic adjustments to improve margins.

Negative Cash Flow

Negative cash flow indicates operational inefficiencies and may limit the company's ability to fund new projects or manage debt.

Operational Challenges

Negative operating margins suggest inefficiencies in core operations, necessitating a focus on cost management and process improvements.

ImExHS Limited Business Overview & Revenue Model

Company Description

ImExHS Limited offers cloud-based medical imaging solutions in Australia and internationally. It offers a medical imaging software that is focused on the development and sale of modular imaging systems, which include information systems for radiology, cardiology, and pathology, as well as a picture archiving and communications system. The company's solutions include AQUILA, a radiology software solution; ALULA, a pathology software solution; Antero, a cardiology software solution; and STELLA.I, a set of artificial intelligence tools in the cloud that support specialists in the diagnosis. It also provides outsourced radiology services for hospitals and other establishments, as well as teleradiology services. The company was incorporated in 2001 and is based in Mascot, Australia.

How the Company Makes Money

ImExHS Limited generates revenue through multiple streams, primarily focusing on direct sales of its healthcare products to hospitals, clinics, and retail distributors. The company also engages in strategic partnerships with international manufacturers, allowing it to import unique medical devices and pharmaceuticals that are then sold in various markets. Additionally, IME may earn income through value-added services such as logistics and supply chain management for its partners. The company's revenue model is bolstered by its strong relationships with healthcare providers and an emphasis on compliance with regulatory standards, which enhances its credibility and customer trust.

ImExHS Limited Financial Statement Overview

Summary

ImExHS Limited exhibits strong revenue growth and a solid equity base, but struggles with profitability and cash flow management. The company shows potential for improvement if operational efficiencies and cash flow management are enhanced.

Income Statement

ImExHS Limited showed a promising revenue growth with a 35.1% increase from 2023 to 2024, and gross profit margin improved to 41.5%. However, the company remains unprofitable with a negative net profit margin of -9.9%, and both EBIT and EBITDA margins are negative, indicating operational challenges.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.08, suggesting low financial leverage. However, the return on equity is negative at -18.1%, reflecting overall losses. The equity ratio stands at 66.4%, indicating a stable equity position relative to total assets.

Cash Flow

Cash flow analysis reveals a negative free cash flow of -1693984 in 2024, with a significant decline in free cash flow compared to 2023. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting net income into cash flow. There is a need for improved cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.35M	26.57M	19.67M	17.12M	13.37M	10.91M
Gross Profit	11.08M	11.03M	3.50M	3.52M	5.22M	2.70M
EBITDA	-913.75K	45.58K	-1.26M	-744.21K	-3.00M	-1.30M
Net Income	-4.11M	-2.63M	-4.19M	-3.04M	-4.70M	-3.62M
Balance Sheet
Total Assets	22.81M	21.81M	22.65M	20.99M	25.01M	20.80M
Cash, Cash Equivalents and Short-Term Investments	2.50M	2.07M	2.36M	1.91M	4.19M	10.80M
Total Debt	1.36M	1.19M	1.29M	1.12M	2.40M	1.70M
Total Liabilities	8.36M	7.33M	6.67M	5.09M	8.36M	5.27M
Stockholders Equity	14.45M	14.47M	15.98M	15.90M	16.65M	15.54M
Cash Flow
Free Cash Flow	-1.87M	-1.69M	414.59K	-4.23M	-5.53M	-3.65M
Operating Cash Flow	-654.08K	-634.68K	2.61M	-2.20M	-2.97M	-1.47M
Investing Cash Flow	-1.47M	-765.91K	-2.13M	-2.22M	-3.39M	-2.19M
Financing Cash Flow	2.68M	1.18M	-98.61K	2.25M	-161.78K	7.40M

ImExHS Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IME, the sentiment is Positive. The current price of 0.34 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.28, and above the 200-day MA of 0.30, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 70.75 is Negative, neither overbought nor oversold. The STOCH value of 86.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IME.

ImExHS Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IME	59 Neutral	AU$15.10M	-3.26	-27.84%	―	6.77%	-8.45%
PCK	55 Neutral	AU$74.13M	-8.12	-8647.54%	―	25.98%	22.10%
RHT	52 Neutral	AU$23.25M	-12.89	-17.05%	―	28.91%	-1050.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BMT	51 Neutral	AU$58.12M	-9.39	-13.83%	―	3.61%	-17.03%
MDR	40 Underperform	AU$16.45M	-0.24	-240.60%	―	-48.41%	-7200.00%
SHG	40 Underperform	AU$84.39M	-11.89	―	―	―	―

ImExHS Limited Corporate Events

IMEXHS CEO Opts for Salary Sacrifice in Exchange for Company Options

IMEXHS Limited announced that CEO Dr. German Arango will sacrifice approximately 50% of his salary for six months in exchange for nil-price options, pending shareholder approval. This move aligns the CEO’s interests with shareholders and reflects his commitment to the company’s future, as the Long Term Incentive Plan has not yet vested options to executives.

IMEXHS Limited Reports Strong Q3 FY25 Performance with Revenue and EBITDA Growth

IMEXHS Limited reported a strong Q3 FY25 with revenue growth of 9% year-on-year, reaching $7.2 million, and a year-to-date revenue of $20.8 million. The company achieved an underlying EBITDA of $0.6 million for the quarter, marking a significant improvement from break-even in the previous corresponding period. The company has successfully expanded its partner program and secured new contracts, contributing to a total software NARR of $417,000 for the quarter. IMEXHS aims to continue strengthening its software business and improving margins through disciplined execution and strategic partnerships.

ImExHS Limited Announces Quotation of New Securities on ASX

ImExHS Limited has announced the issuance of 267,424 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move, part of an employee incentive scheme, is expected to enhance the company’s operational flexibility and could potentially strengthen its market position by aligning employee interests with corporate growth objectives.

ImExHS Limited Updates Director’s Shareholding

ImExHS Limited has announced a change in the director’s interest, specifically involving Carlos Jaime Palacio. The update reveals that Mr. Palacio has acquired 53,485 fully paid ordinary shares in lieu of director fees for the quarters ending June and September 2025, increasing his direct holdings to 325,442 shares. This change reflects the company’s practice of compensating directors with shares, which may align their interests more closely with those of shareholders.

ImExHS Limited Announces Director’s Interest Change

ImExHS Limited has announced a change in the director’s interest notice, specifically involving Douglas Lingard. On September 8, 2025, Mr. Lingard acquired 53,485 fully paid ordinary shares directly, in lieu of non-executive director fees for the quarters ending June 30 and September 30, 2025. This acquisition reflects a strategic decision to align director compensation with company performance, potentially impacting investor perceptions and stakeholder confidence in the company’s governance practices.

ImExHS Limited Announces Director’s Interest Change

ImExHS Limited has announced a change in the director’s interest notice, specifically regarding Damian Banks. The change involves the acquisition of 53,485 fully paid ordinary shares by Damian Banks, issued in lieu of non-executive director fees for the quarters ending June and September 2025. This adjustment reflects the company’s ongoing management and allocation of director compensation, potentially impacting shareholder perceptions and the company’s governance practices.

ImExHS Limited Announces Director’s Share Acquisition

ImExHS Limited has announced a change in the director’s interest, specifically regarding Douglas Flynn’s holdings. The company disclosed that Mr. Flynn acquired 106,969 fully paid ordinary shares in lieu of non-executive director fees for the quarters ending June and September 2025. This acquisition reflects a strategic decision to compensate directors with shares, potentially aligning their interests more closely with those of shareholders.